Advanced Proteome Therapeutics (APC) (CVE:APC) says it has consummated an agreement with the University of Iowa for Dr. Joel Shilyansky to test the effects of the company's protein conjugates and multimers, as part of the development of APC's Foundation Trinity cancer technology.
The deal completes one of the six-month goals the company set out for itself in February this year.
Advanced Proteome has a potential three-in-one cancer treatment that acts as a targeted, combination and homogeneous therapy - all in a single agent. The company's technology is based on a proprietary platform that can be used to attach known therapeutics to specific sites on proteins - in this case, proteins that have shown affinity for specific cancer cells, hence the targeted and combination therapy.
The attachments are designed to boost the properties of the protein targeted for the specific cancer cells, giving it additional therapeutic abilities.
The homogeneity aspect of Advanced Proteome's therapy originates from the use of a protein not only as a delivery system, but also as a scaffold on which to attach each anti-cancer entity to its own specific site on the protein, and allows the company to produce single agents, or protein conjugates, bearing multiple therapies.
"As part of our program of preclinical testing of APC's proprietary protein modifications, we are excited about the prospect of having Dr. Shilyansky and his colleagues evaluate the effects of APC's protein conjugates and multimers in their highly sophisticated experimental models and assays," said president and CEO of APC, Dr. Allen Krantz, in a statement Monday.
Dr. Shilyansky, who holds the Robert and Helcne Soper Chair of Pediatric Surgery at the University of Iowa Carver College of Medicine, and his staff, will be performing the testing of APC's protein modifications in University of Iowa laboratories to determine their effects on tumor growth and immunogenicity.
A focal point of his interest, APC said Monday, is "the protection from tumor challenge, afforded by proteins with high affinity for cancers cells, through immune-mediated mechanisms".
Last week, the company told investors that it received a notice of issuance for its U.S. patent application covering chemical modifications of proteins targeted for cancer cells. The notification indicated an issue date of April 30. The company said it is also pursuing patent applications related to the Foundation Trinity technology in multiple jurisdictions outside the United States.